48 related articles for article (PubMed ID: 15913885)
1. Diversity in neuroblastomas and discrimination of the risk to progress.
Tanaka T; Iehara T; Sugimoto T; Hamasaki M; Teramukai S; Tsuchida Y; Kaneko M; Sawada T
Cancer Lett; 2005 Oct; 228(1-2):267-70. PubMed ID: 15913885
[TBL] [Abstract][Full Text] [Related]
2. Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV.
Kyo Y; Tanaka T; Hayashi K; Iehara T; Kaneko M; Hosoi H; Sugimoto T; Hamasaki M; Kobayashi M; Sawada T
Cancer Lett; 2011 Jul; 306(1):27-33. PubMed ID: 21486686
[TBL] [Abstract][Full Text] [Related]
3. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
4. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol.
Navarro S; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Mosseri V; De Bernardi B; Michon J; Peuchmaur M;
J Clin Oncol; 2006 Feb; 24(4):695-9. PubMed ID: 16446343
[TBL] [Abstract][Full Text] [Related]
6. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
8. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
9. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
10. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients.
Hiyama E; Yamaoka H; Kamimatsuse A; Onitake Y; Hiyama K; Nishiyama M; Sueda T
J Pediatr Surg; 2006 Dec; 41(12):2032-6. PubMed ID: 17161199
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
[TBL] [Abstract][Full Text] [Related]
14. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
Goldsmith KC; Hogarty MD
Cancer Lett; 2005 Oct; 228(1-2):133-41. PubMed ID: 15927359
[TBL] [Abstract][Full Text] [Related]
15. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
16. Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma.
Chughtai SA; Genus T; Ramani P; Dyer S; Powell JE; McMullan D; Davison V; McConville CM;
Eur J Cancer; 2006 Aug; 42(12):1826-34. PubMed ID: 16872824
[TBL] [Abstract][Full Text] [Related]
17. Retroperitoneal ganglioneuroblastoma resected 8 years after mass screening: a case report.
Nakaoka T; Uemura S; Nakagawa Y; Yano T; Oda M
J Pediatr Surg; 2007 Nov; 42(11):E29-32. PubMed ID: 18022424
[TBL] [Abstract][Full Text] [Related]
18. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.
Oberthuer A; Warnat P; Kahlert Y; Westermann F; Spitz R; Brors B; Hero B; Eils R; Schwab M; Berthold F; Fischer M
Cancer Lett; 2007 Jun; 250(2):250-67. PubMed ID: 17126996
[TBL] [Abstract][Full Text] [Related]
19. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine.
Prochazka P; Hrabeta J; Vícha A; Eckschlager T
Cancer Genet Cytogenet; 2010 Jan; 196(1):96-104. PubMed ID: 19963143
[TBL] [Abstract][Full Text] [Related]
20. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]